Ultrasonography-guided foam sclerotherapy in patients with small saphenous vein insufficiency

J Vasc Surg Venous Lymphat Disord. 2020 Sep;8(5):799-804. doi: 10.1016/j.jvsv.2020.01.011. Epub 2020 Mar 14.

Abstract

Purpose: Chronic venous insufficiency is an important health problem; small saphenous vein (SSV) insufficiency is one of the leading causes and may affect up to 20% of adults. In addition to conventional treatment methods, endovenous treatment techniques have become popular in treatment of varicose veins. Herein, we report the outcomes of ultrasound-guided foam sclerotherapy (UGFS) in patients with symptomatic SSV insufficiency.

Methods: From January 2014 to June 2018, patients with primary SSV insufficiency treated with UGFS were followed to assess the effectiveness and safety of the procedure. A total of 31 lower limbs of 30 patients (18 females and 12 males), who attended control visits at 1 week, 1, 3, and 6 months, and yearly, after undergoing UGFS, were included in the study. The clinical results, occlusion rates, and the patients' preprocedure and postprocedure Venous Clinical Severity Scores were recorded.

Results: The records show that, during the procedure, severe pain occurred at the time of injection in one patient (3%), vasovagal syncope in one patient (3%), hyperpigmentation in five patients (16%), and phlebitis in three patients (9%). It was also recorded that during follow-up 24 legs (78%) showed complete thrombosis and 7 legs (22%) had partial thrombosis. The mean Venous Clinical Severity Score for the patients before UGFS was 8.58 ± 3.78, and 7.25 ± 3.17 after the procedure. No major complications, including sural nerve injury and deep venous thrombosis, were seen during the follow-up period.

Conclusions: The results of this study show that UGFS is a simple, safe, and effective procedure for treatment in patients with symptomatic SSV insufficiency with acceptable side effects.

Keywords: Foam sclerotherapy; Small saphenous vein; Superficial venous reflux.

MeSH terms

  • Adult
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Middle Aged
  • Polidocanol / administration & dosage*
  • Polidocanol / adverse effects
  • Prospective Studies
  • Saphenous Vein* / diagnostic imaging
  • Saphenous Vein* / physiopathology
  • Sclerosing Solutions / administration & dosage*
  • Sclerosing Solutions / adverse effects
  • Sclerotherapy* / adverse effects
  • Time Factors
  • Treatment Outcome
  • Ultrasonography, Interventional*
  • Venous Insufficiency / diagnostic imaging
  • Venous Insufficiency / physiopathology
  • Venous Insufficiency / therapy*

Substances

  • Sclerosing Solutions
  • Polidocanol